Moss, 1 November 2021
Gentian Diagnostics ASA is pleased to announce that the results from a study
conducted in collaboration with Charité - Universitätsmedizin Berlin and Labor
Berlin have been presented as a poster at the European Society for Emergency
Medicine (EUSEM) congress in Lisbon.
The results are part of an ongoing prospective clinical trial (CASCADE) which is
performed in the Emergency department of the Charité - Universitätsmedizin
Berlin Campus Benjamin Franklin.
The study concluded that the calprotectin levels in plasma were significantly
higher in ventilated than in non-ventilated COVID-19 patients. Moreover,
calprotectin was able to predict need for Intensive Care Unit (ICU) admission
with outstanding performance and an AUROC of 1.0. The performance of
calprotectin in prediction of ICU admission was better than performance of the
10 COVID-19 patients with positive SARS-CoV-2 PCR test were enrolled and the
value of calprotectin in prediction of need for admission to ICU and the need
for mechanical ventilation was also investigated.
The conclusion from this study supports calprotectin as an early biomarker for
risk stratification and optimal management of COVID-19 patients. Early
identification of patients with severe form of the disease is of critical
importance for optimal patient care and use of healthcare resources. The authors
also confirm that use of Gentian's calprotectin assay GCAL® supports an easily
accessible and efficient measurement of calprotectin in routine laboratories.
For further information please see the enclosed poster.
Njaal Kind, CFO and COO
+47 919 06 525 (mobile)
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.